BCR-ABL1 Minor Quantification (Pilot - Not Accredited)

 

BCR-ABL1 rearrangements at the minor breakpoint cluster region (m-BCR), leading to production of the p190 fusion protein, are most frequently associated with Ph-positive Acute Lymphocytic Leukaemia (ALL) and a small subset of Chronic Myeloid Leukaemia (CML) patients. Quantification of minor BCR-ABL1 transcript levels can be utilised to monitor patient response to treatment and disease recurrence.

 

In this new pilot programme for 2014/15, participants are provided with lyophilised cell line material for quantitative analysis of the BCR-ABL1 minor transcript. Participants are asked to submit quantitative results as %BCR-ABL1/control gene together with details of their methodology. Instructions for the storage, reconstitution and use of the lyophilised samples are included with each sample send-out. Two distributions are issued per annum, with each send-out consisting of two samples.

 

No activities in relation to this EQA programme are subcontracted.

 

To register for this programme, please click here.

Example BCR-ABL1 Minor Quantification (Not Accredited) Report
Trial mBCRQ 171801 v1.0.0 Report Example[...]
Adobe Acrobat document [614.6 KB]
BCR-ABL1 Minor Quantification (Not Accredited) 181902 Results Form
mBCRQ 181902 results form_for website.pd[...]
Adobe Acrobat document [180.0 KB]
Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 24/04/19 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information, please click here.


Please click here for our privacy policy.


The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).